WO2023057879 - METHODS AND PRODUCTS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDERS
National phase entry:
Publication Number
WO/2023/057879
Publication Date
13.04.2023
International Application No.
PCT/IB2022/059429
International Filing Date
03.10.2022
Title **
[English]
METHODS AND PRODUCTS FOR TREATING SUBJECTS WITH AUTISM SPECTRUM DISORDERS
[French]
PROCÉDÉS ET PRODUITS POUR TRAITER DES SUJETS ATTEINTS DE TROUBLES DU SPECTRE AUTISTIQUE
Applicants **
NEURIM PHARMACEUTICALS (1991) LTD.
Inventors
ZISAPEL, Nava
LAUDON, Moshe
Priority Data
63/251,935
04.10.2021
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3288 | |
| EPO | Filing, Examination, Granting | 32691 | |
| Japan | Filing, Examination, Granting | 3386 | |
| South Korea | Filing, Examination, Granting | 4585 | |
| USA | Filing, Examination, Granting | 11740 |
Total:
55,690
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
Methods and products for treating a subject diagnosed with an autism spectrum disorder, an intellectual disability, an anxiety disorder, a mood disorder, a disorder of social interaction, irritability, aggression, self-injurious behavior, hyperactivity, inattention, or Fragile X syndrome or brain neuroinflammation by administering a tablet or liquid or a solid ODT or ODF or SMEDDS containing a ticagrelor or ticagrelor salt or combination with a second agent which may include a magnesium ion containing-compound, a zinc ion containing-compound, a lysine or lysine salt, an arginine or arginine salt, lecithin, or a combination thereof, wherein the ODT or ODF or SMEDDS releases >50% of the ticagrelor or a pharmaceutically acceptable salt thereof and >50% of the second agent within 15 minutes.[French]
L'invention concerne des procédés et des produits pour le traitement d'un sujet diagnostiqué avec un trouble du spectre autistique, une déficience intellectuelle, un trouble de l'anxiété, un trouble de l'humeur, un trouble de l'interaction sociale, de l'irritabilité, de l'agressivité, un comportement d'automutilation, une hyperactivité, une inattention ou le syndrome de l'X fragile ou une neuro-inflammation cérébrale par l'administration d'un comprimé ou d'un liquide ou d'un ODT ou ODF ou SMEDDS solide contenant un ticagrélor ou un sel de ticagrélor ou une combinaison avec un deuxième agent qui peut inclure un composé contenant des ions de magnésium, un composé contenant des ions de zinc, une lysine ou un sel de lysine, une arginine ou un sel d'arginine, de la lécithine, ou une combinaison de ceux-ci, l'ODT ou l'ODF ou le SMEDDS libérant > 50 % du ticagrélor ou d'un sel pharmaceutiquement acceptable de celui-ci et > 50 % du deuxième agent en 15 minutes.